Stoke Therapeutics Highlights Zorevunersen Data at EEC
ATHENS, Greece, September 1, 2026 Stoke Therapeutics and Biogen announced presentations of clinical data supporting the potential of zorevunersen,...
epilepsy
Advertisement
Biohaven, SK Biopharmaceuticals Sign Global Opakalim Deal
NEW HAVEN, Conn. and SEOUL, South Korea, Aug. 26, 2026 Biohaven Ltd. and SK Biopharmaceuticals announced a strategic global...
Ceribell Secures CMS NTAP for Delirium Monitor System
SUNNYVALE, Calif., Aug. 3, 2026 Ceribell, Inc. has secured a significant reimbursement milestone after the U.S. Centers for Medicare...
Supernus Pharmaceuticals and Indivior to Merge in $2.2 Billion CNS Biopharma Deal
ROCKVILLE, Md. & RICHMOND, Va., Aug. 3, 2026 Supernus Pharmaceuticals and Indivior Pharmaceuticals announced they have entered into a...
Lundbeck Completes Enrollment in Phase III DEEp OCEAN Trial
VALBY, Denmark, July 20, 2026 H. Lundbeck A/S has reached a major clinical development milestone with the last patient...
Advertisements
Marengo Reports Phase II Breast Cancer Trial Success
CAMBRIDGE, Mass., April 17, 2026 Marengo Therapeutics has unveiled encouraging late-breaking Phase IIa clinical results for its investigational immunotherapy...
Praxis Precision Medicines Extends FDA Review for Relutrigine NDA
BOSTON, June 29, 2026 Praxis Precision Medicines announced that the U.S. Food and Drug Administration (FDA) has extended the...
SK Life Science NDA for Cenobamate Suspension Accepted
PARAMUS, N.J., June 15, 2026 SK Life Science, Inc. has announced that the U.S. Food and Drug Administration (FDA)...
UCB Acquires Neurona to Advance Epilepsy Cell Therapy
BRUSSELS, Belgium, April 17, 2026 UCB, a global biopharmaceutical leader, has announced a definitive agreement to acquire Neurona Therapeutics...
Neurelis Shows Strong Seizure Control Data for VALTOCO at AAN
SAN DIEGO, Calif., April 16, 2026 Neurelis, Inc. has announced new clinical and real-world analyses demonstrating the effectiveness of...
Advertisement
